Vaxxinity, Inc. announced a research collaboration with the University of Florida?s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity?s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option. Researchers at UF will conduct a series of preclinical studies to explore the effects of Vaxxinity?s candidates for neurodegenerative disease on relevant biological targets, such as beta-amyloid, tau, and alpha-synuclein, in various in vitro and in vivo studies, including models of disease and antibody-target binding assays.

This project will complement preclinical work conducted at Vaxxinity, which has already shown immunogenicity, target engagement, and efficacy in animal models of multiple neurodegenerative diseases including Alzheimer?s and Parkinson?s. Vaxxinity?s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets. The Company will provide materials, including candidates derived from its platform and antibodies generated by active immunotherapy treatment, to support the collaborative research at UF.